帕博西利布
癌症研究
细胞周期蛋白依赖激酶
医学
细胞周期
细胞周期蛋白依赖激酶4
癌症
靶向治疗
乳腺癌
药理学
内科学
转移性乳腺癌
细胞周期蛋白依赖激酶2
作者
Ziqi Liu,Tao Zuo,Feng Xu,Ping Xu
出处
期刊:PubMed
[National Institutes of Health]
日期:2021-07-25
卷期号:37 (7): 2232-2239
标识
DOI:10.13345/j.cjb.200455
摘要
The development and progression of most cancers have been well recognized as the result of highly activated cell cycle. Cyclin dependent kinase 4/6 plays important roles not only in mitosis, but also in multiple biological processes that contribute to cancer development, such as aging, apoptosis and histone modification. Three FDA approved CDK4/6 inhibitors, Palbociclib, Ribociclib and Abemaciclib, have been used as targeted cancer therapeutic agents to benefit patients with endocrine therapy-resistant breast cancer and other types of cancer, prolonging their survival. However, the clinical application of these inhibitors also leads to acquired drug resistance and other problems. This paper reviews the regulatory roles of CDK4/6, the application of CDK4/6 inhibitors in cancer and the challenge of drug resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI